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Objective. The C-type natriuretic peptide (CNP)
signaling pathway is a major contributor to postnatal
skeletal growth in humans. This study was undertaken
to investigate whether CNP signaling could prevent
growth delay and cartilage damage in an animal model
of inflammatory arthritis.
Methods. We generated transgenic mice that
overexpress CNP (B6.SJL-Col2a1-NPPC) in chondro-
cytes. We introduced the CNP transgene into mice with
experimental systemic inflammatory arthritis (K/BxN T
cell receptor [TCR]) and determined the effect of CNP
overexpression in chondrocytes on the severity of arthri-
tis, cartilage damage, and linear growth. We also exam-
ined primary chondrocyte cultures for changes in gene
and protein expression resulting from CNP overexpres-
sion.
Results. K/BxN TCR mice exhibited linear growth
delay (P < 0.01) compared to controls, and this growth
delay was correlated with the severity of arthritis.
Diminished chondrocyte proliferation and matrix pro-
duction was also seen in K/BxN TCR mice. Compared to
non–CNP-transgenic mice, K/BxN TCR mice with over-
expressed CNP had milder arthritis, no growth delay,
and less cartilage damage. Primary chondrocytes from
mice overexpressing CNP were less sensitive to inflam-
matory cytokines than wild-type mouse chondrocytes.
Conclusion. CNP overexpression in chondrocytes
can prevent endochondral growth delay and protect
against cartilage damage in a mouse model of inflam-
matory arthritis. Pharmacologic or biologic modulation
of the CNP signaling pathway may prevent growth
retardation and protect cartilage in patients with in-
flammatory joint diseases, such as juvenile idiopathic
arthritis.
Linear growth results from the action of multiple
signaling pathways. The pathway that includes C-type
natriuretic peptide (CNP) contributes to chondrocyte
proliferation, differentiation, and matrix synthesis in
skeletal growth plates (1–4). Patients with homozygous
loss-of-function mutations in natriuretic peptide recep-
tor B (NPR-B), the CNP receptor, have acromesomelic
dysplasia (5), and carriers of the heterozygous mutation
frequently have short stature (6). Also, patients with
chromosome translocations that cause CNP overexpres-
sion develop skeletal overgrowth (7). These conditions
indicate a dose-dependent effect of CNP signaling on
linear growth. Therefore, linear growth may be affected
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78in patients with acquired diseases that alter the produc-
tion of CNP or the expression of its receptor, NPR-B.
Children with juvenile inflammatory arthritis
(JIA) have impaired linear growth, and 40% develop
bone degeneration and deformity adjacent to affected
joints (8–11). The mechanism by which chronic systemic
inflammation suppresses linear growth in children with
JIA is not completely understood (12,13). Alterations in
growth hormone and insulin-like growth factor (IGF)
signaling pathways have been associated with growth
delay in children with chronic arthritis. Although serum
growth hormone levels were unchanged in patients with
JIA, patients did have reduced levels of IGF-1 and IGF
binding protein 3 (IGFBP-3) (14), suggesting that in-
flammation causes growth hormone resistance. The
CNP signaling pathway has not been studied in children
with JIA.
Animal models of inflammatory arthritis have
been used to delineate pathways that contribute to
impaired linear growth and joint deformity (15). Local
elevations of tumor necrosis factor  (TNF),
interleukin-6 (IL-6), and IL-1 levels have been ob-
served in affected growth plates. Furthermore, over-
expression of IL-6 (16) or TNF (17) in transgenic mice
causes systemic inflammatory arthritis and growth retar-
dation. By 25 days of age, K/BxN T cell receptor (TCR)
mice exhibit pronounced joint inflammation that resem-
bles rheumatoid arthritis (17–19). Herein, we report that
these mice also develop linear growth delay and cartilage
damage that can be lessened by overexpression of CNP
in chondrocytes.
MATERIALS AND METHODS
These experiments were approved by the Institutional
Animal Care and Use Committee at Case Western Reserve
University.
Generation of CNP-transgenic mice. We cloned full-
length human CNP (NPPC) complementary DNA (cDNA)
into the pKN185 vector, which drives CNP expression under
the control of Col2a1 promoters and enhancers (20). Col2a1-
NPPC–transgenic mice were produced following pronuclear
injection into zygotes on a mixed C57BL/6J-SJL background.
One founder animal that had 4 copies of the CNP transgene
integrated into a single locus, as determined by Southern
blotting and Mendelian segregation of the transgene, was then
backcrossed for 20 generations onto the C57BL/6J back-
ground. C57BL/6J mice were also used as wild-type (WT)
controls.
Development of the K/BxN TCR mouse model of
arthritis. KRN TCR–transgenic mice, as well as K/BxN TCR
mice that develop spontaneous arthritis, have been previously
described (21–23). KRN TCR–transgenic mice were a gift
from CBDM Lab (Joslin Diabetes Center/Harvard Medical
School). K/BxN TCR mice were obtained by crossing KRN
TCR–transgenic mice with nonobese diabetic mice (NOD/
ShiLtJ; The Jackson Laboratory). Only offspring that inherited
the TCR transgene developed inflammatory arthritis on this
background; mice that did not inherit the TCR transgene were
used as nontransgenic controls.
Breeding the CNP transgene into the mice with exper-
imental arthritis. We bred Col2a1-NPPC–transgenic mice
with KRN TCR mice. Offspring that carried both the Col2a1-
NPPC and the TCR transgenes were then bred with NOD
mice. The phenotypes of offspring that were double heterozy-
gous for the TCR and Col2a1-NPPC transgenes (K/BxN
TCR,Col2a1-NPPC) were compared to the phenotypes of
offspring that only inherited the TCR transgene (K/BxN
TCR). Other offspring resulting from this cross included mice
heterozygous for the Col2a1-NPPC transgene only and mice
that inherited neither transgene (BxN). Offspring were exam-
ined at birth and weekly, from 3 weeks of age until 20 weeks of
age.
Small-animal radiography. A Faxitron radiographic
inspection unit (model 8050-010; Field Emission) was used to
obtain radiographic images of the mice postmortem. Legs were
exposed for 1.5 minutes at 35 kVp; the entire body was exposed
for 1.5 minutes at 30 kVp.
Clinical scoring of arthritis severity. The severity of
clinical arthritis was determined using a previously described
scoring system (24,25), with modifications (available online at
http://www.case.edu/artsci/biol/skeletal/24114569s.html).
Higher scores indicate increased severity of clinical arthritis.
Sample collection. Mice were bled under sedation
and then euthanized. Samples were collected from mice that
were 1, 2, 3, 4, 6, 8, 12, 16, and 24 months old. To evaluate the
growth plates, one hind leg (femur and tibia) from each mouse
was dissected, fixed with 4% formaldehyde in phosphate
buffered saline (PBS) for 24 hours at 4°C, decalcified with
0.5M EDTA for 1 week, and then embedded in paraffin.
Coronal sections measuring 4 m across the femorotibial joint
were stained with Safranin O–fast green or hematoxylin and
eosin and analyzed by immunohistochemical staining or in situ
hybridization. For accurate measurement of articular cartilage
and growth plate cartilage, sections were obtained at the point
where the anterior cruciate ligament inserts into the tibia.
Histologic scoring system. Histologic evaluation of
inflammation in the knee joint and cartilage integrity was
performed using two scoring systems. The histologic scoring
system described by Pettit et al (26) was used to assess the
severity of inflammatory arthritis. The International Cartilage
Repair Society scoring system (27) was used to assess the
status of the extracellular matrix repair in joint cartilage
(available online at http://www.case.edu/artsci/biol/skeletal/
24114569s.html). An investigator who was not otherwise in-
volved with the study evaluated the mouse knee sections under
blinded conditions and assigned a score based on these sys-
tems.
Cell proliferation analysis by bromodeoxyuridine
(BrdU) labeling. BrdU (300 mg/kg dose; Zymed) was injected
intraperitoneally. Mice were euthanized 2 hours after injec-
tion. Tissue was processed and embedded in paraffin as
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BrdU-staining kit according to the instructions of the manu-
facturer (Zymed). The percentage of BrdU-positive cells was
determined by dividing the number of BrdU-positive chondro-
cytes by the total number of chondrocytes that were counted in
multiple sections of the growth plate.
In situ hybridization. Slides were deparaffinized and
fixed in 4% formaldehyde. Sections were digested with protei-
nase K (1 g/ml) for 20 minutes at 37°C and acetylated in
0.25% acetic anhydride in 0.1M triethanolamine HCl. After
refixation in 4% formaldehyde, sections were hybridized with
35S-labeled riboprobes in hybridization buffer (50% deionized
formamide, 300 mM NaCl, 20 mM Tris HCl, pH 8.0, 5 mM
EDTA, 0.5 mg/ml yeast transfer RNA, 10% dextran sulfate,
and 1 Denhardt’s solution) in a humidified chamber at 55°C
overnight. After hybridization, slides were washed with 5
saline–sodium citrate (SSC) at 50°C, 50% formamide, 2 SSC
at 65°C, and 1 NTE (0.5 M NaCl, 10 mM Tris HCl, pH 8.0,
5m M EDTA) at 37°C, and then treated with RNase A (20
g/ml) and RNase T1 (1 unit/l) in 1 NTE at 37°C for 20
minutes. Slides were further washed in 1 NTE at 37°C, 50%
formamide, 2 SSC at 65°C, 2 SSC, 0.1 SSC, and then
dehydrated with graded concentrations of ammonium acetate
and ethanol. Slides were dipped in NTB emulsion (Kodak) and
exposed to the emulsion for 6 weeks, after which they were
developed and counterstained with Hoechst 33258 (Sigma).
The NPPC probe was made from the pKN185-hCNP vector
construct that was originally used to create the transgenic mice.
A5  280-bp fragment of the human CNP cDNA sequence plus
118 bp of upstream vector sequence was used for sense and
antisense probes (398 bp).
Primary chondrocyte isolation and cytokine treat-
ment. Primary chondrocytes from rib cages of 5-day-old mice
were isolated by enzymatic digestion using standard methods
(28). Briefly, rib cages were collected in sterile PBS. The ribs
were rinsed several times before digestion with 10 ml of 3
mg/ml collagenase B (Worthington) in Dulbecco’s modified
Eagle’s medium (DMEM) for 1 hour at 37°C. The ribs were
then washed several times with PBS and digested overnight at
37°C with collagenase solution (2 ml of 3 mg/ml collagenase
B/DMEM plus 10 ml DMEM with 10% fetal bovine serum).
The next day, the cell suspension was strained and the cells
were pelleted at 1,000 revolutions per minute for 10 minutes
and then resuspended in DMEM containing 10% fetal bovine
serum, penicillin (100 units/ml), streptomycin (100 g/ml), and
amphotericin B (0.25 g/ml). Viable cell counts were deter-
mined by trypan blue staining, and cells were seeded at a
density of 1  10
6 cells per 35-mm culture plate in 2.5 ml
DMEM (1.2  10
5 cells/cm
2). Cells were grown in culture
medium until 90% confluent, with a change of medium every
3 days. Once cells became 90% confluent, chondrocyte
cultures were serum-starved and treated with cytokines (10
ng/ml TNF or 10 ng/ml IL-1; both from R&D Systems)
overnight (18 hours) and messenger RNA (mRNA) and
proteins were extracted as previously described (29).
Western blotting. Cells were lysed in 500 l of buffer
(50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100,
0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1
mM EDTA, 1 mM EGTA, and Complete protease inhibitor
cocktail), and total lysate protein (60 g/lane) was resolved
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
transferred to nitrocellulose membranes (Bio-Rad), blocked
with nonfat dry milk, resuspended in Tris buffered saline,
and probed with primary and secondary antibodies as previ-
ously described (29,30). Primary antibodies included anti-
phosphorylated and anti-nonphosphorylated p38 MAPK and
ERK-1/2 (p38 MAPK phosphorylated #4631, p38 MAPK
nonphosphorylated #9212, phospho–ERK-1/2–phospho-
MAPK [Thr202/Ty204] [Cell Signaling Technologies]) and
anti–NPR-B (sc-25486; Santa Cruz Biotechnology). Immuno-
reactive proteins were visualized by using 1:1,000 diluted
horseradish peroxidase (HRP)–linked secondary antibodies
and enhanced chemiluminescence (GE Healthcare) as de-
scribed (31). HRP-conjugated goat anti-rabbit IgG at a dilu-
tion of 1:2,000 (sc-2004; Santa Cruz Biotechnology) was used
as the secondary antibody for NPR-B.
RNA extraction and cDNA synthesis. Total cyto-
plasmic RNA was prepared from primary chondrocytes using
an RNeasy kit (Qiagen). RNA (2 g) was reverse transcribed
using a SuperScript II reverse-transcriptase kit (Invitrogen),
and the cDNA mixture was diluted 5-fold in nuclease-free
water; 5 l was used for real-time quantitative polymerase
chain reaction (qPCR).
Real-time qPCR. Using a StepOnePlus thermocycler
(Applied Biosystems), reactions were performed in a 20-l vol-
ume with 0.5 M of each primer and SYBR Green Master Mix
according to the instructions of the manufacturer (Qiagen).
The expression level of the housekeeping gene Rlp7 was used
to normalize mRNA expression. Information on the primers
used to amplify specific cDNA sequences is available online at
http://www.case.edu/artsci/biol/skeletal/24114569s.html. All re-
actions were performed in duplicate.
Statistical analysis. Disease severity and histopatho-
logic scores were compared between groups, using chi-square
tests for categorical variables (clinical and histologic scores)
and t-tests for continuous variables. Results are expressed as
the mean  SD. To test differences between the groups of
mice, data on the nose-to–tail tip length of mice were exam-
ined by analysis of variance (ANOVA). ANOVA F test results
were reported. P values less than 0.05 were considered signif-
icant. We also used Pearson correlation matrices to test for
correlations between the clinical and histopathologic data. The
data were analyzed using SAS 9.0 and Stata 11.0.
RESULTS
Col2a1-NPPC–transgenic mice exhibit linear
bone overgrowth. Mice carrying the CNP transgene
driven by the Col2a1 promoter/enhancer (Col2a1-
NPPC) demonstrated skeletal overgrowth at 4 weeks of
age (available online at http://www.case.edu/artsci/biol/
skeletal/24114569s.html). Overgrowth affected the long
bones and the vertebrae (Figures 1A and B) and was
associated with increases in growth plate width, the size
of hypertrophic chondrocytes (P  0.01 by F test)
(Figures 1C and D), nose-to–tail tip length (Figure 1E),
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by F test) (Figure 1F). The mean  SD width of the
growth plate was 148 14 m in Col2a1-NPPC–
transgenic mice (n  12) and 99  5.3 m in nontrans-
genic control mice (n  5) at 4 weeks of age (P  0.05
by Student’s t-test). CNP transgene expression in growth
plate and articular chondrocytes was detected by in situ
hybridization (Figures 1G and H). Col2a1-NPPC–
transgenic mice developed thoracic kyphosis and joint
dislocations over time, but no abnormalities outside of
the skeletal system were detected.
Arthritic K/BxN TCR mice exhibit linear growth
delay and articular cartilage damage. K/BxN TCR mice
developed arthritis by age 3 weeks and exhibited visible
growth delay by age 12 weeks when compared to litter-
mates that did not inherit the TCR transgene (BxN)
(Figure 2A). Significant differences in linear growth (as
determined by nose-to–tail tip length) between K/BxN
TCR mice and BxN littermates were detected by 4 weeks
of age (P  0.05 by F test) (Figure 2B). To prevent length
discrepancies, we did not obtain tissue for DNA isolation
by clipping tails in order to genotype the mice. In the
Figure 1. Longitudinal overgrowth in Col2a1-NPPC–transgenic (TG) mice. A and B, Photograph (A) and radiographs (B) of 24-week-old
nontransgenic wild-type (WT) mice and their female Col2a1-NPPC–transgenic littermates in which C-type natriuretic peptide is overexpressed.
C, Photomicrographs of Safranin O–fast green–stained proximal tibia growth plates from 13-week-old female WT and Col2a1-NPPC–transgenic
mice. Measurements in the growth plates are shown (vertical lines). Bars  100 m. D, Width of hypertrophic chondrocytes in WT and
Col2a1-NPPC–transgenic mice at week 1 (n  3 and n  4, respectively), week 3 (n  4 and n  6, respectively), and week 4 (n  4 and n  5,
respectively). 2-D  2-dimensional. E, Linear growth in male and female WT and Col2a1-NPPC–transgenic mice at week 6 (n  12 and n  16,
respectively), week 9 (n  6 and n  10, respectively), week 11 (n  16 and n  9, respectively), week 13 (n  6 and n  8, respectively), week
15 (n  8 and n  12, respectively), week 20 (n  9 and n  6, respectively), and week 26 (n  9 and n  6, respectively). F, Percent of growth
plate chondrocytes that incorporated bromodeoxyuridine (BrdU) in WT and Col2a1-NPPC–transgenic mice at week 1 (n  4 and n  5,
respectively), week 3 (n  2 and n  4, respectively), and week 4 (n  5 and n  5, respectively). Values in D–F are the mean  SD. G and H,
Photomicrographs showing growth plate (G) and articular cartilage (H) from 4-week-old WT and Col2a1-NPPC–transgenic mice following Hoechst
staining of cell nuclei (top) and in situ hybridization using an antisense NPPC probe (bottom). Original magnification  20. Note the width of the
growth plate (brackets in G). Chondrocytes in G and H are shown (arrows).
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correlated with longitudinal growth; this correlation was
strongest at age 14 weeks (available online at http://
www.case.edu/artsci/biol/skeletal/24114569s.html). The
growth plates in the K/BxN TCR mice were narrower
and had fewer cells than growth plates in the BxN
littermates (Figure 2C). The articular cartilage in K/BxN
TCR mice also became less cellular, had less cartilage
matrix, and had a more irregular surface than the
articular cartilage in BxN mice (Figures 2D and E).
CNP overexpression in chondrocytes improves
linear growth and reduces articular cartilage damage
in K/BxN TCR mice. Since CNP overexpression en-
hanced linear growth in Col2a1-NPPC–transgenic mice,
we sought to determine whether overexpression could
protect against growth impairment in mice with inflam-
matory arthritis. We first bred Col2a1-NPPC–transgenic
mice onto the KRN TCR background and then onto the
K/BxN background (Figure 3A).
In K/BxN TCR mice that overexpressed CNP
Figure 2. Growth retardation and cartilage damage in K/BxN T cell receptor (TCR) mice. A, Photograph of 12-week-old female K/BxN mice with
the TCR transgene (K/BxN TCR) and without the TCR transgene (BxN). Compared with the BxN mouse, the K/BxN TCR mouse is smaller and
has evidence of inflammatory arthritis; the hind paw (arrows) is swollen in the K/BxN TCR mouse. B, Linear growth of male and female BxN and
K/BxN TCR mice. Statistical analysis showed significant differences (P  0.05 by F test) between BxN and K/BxN TCR mice at week 4 (n  12 and
n  10, respectively), week 8 (n  15 and n  8, respectively), week 10 (n  16 and n  8, respectively), and week 14 (n  14 and n  5, respectively).
Values are the mean  SD. C, Photomicrographs of hematoxylin and eosin (H&E)–stained proximal tibia growth plate cartilage from a 9-week-old
female K/BxN TCR mouse and a BxN littermate. The width of the growth plate is shown (vertical lines). Original magnification  40.
D, Photomicrographs of H&E-stained sagittal sections of the femorotibial joint of a 9-week-old female BxN mouse and a K/BxN TCR littermate.
Bars  100 m. E, Photomicrographs of Safranin O–stained coronal sections of the femorotibial joint of a 12-week-old female BxN mouse and a
K/BxN TCR littermate. Bars  100 m. K/BxN TCR mice exhibited cartilage thinning (vertical lines in C and D), chondrocyte loss (arrows in D),
and reduced proteoglycan content compared to BxN mice.
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growth retardation was seen (P  0.05 by F test) (Figure
3B), growth plates were increased in width (Figure 3C
and online at http://www.case.edu/artsci/biol/skeletal/
24114569s.html), and long bones were increased in
length (Figure 3D) compared to K/BxN TCR arthritic
mice. The increase in growth plate width in mice with
the Col2a1-NPPC transgene was associated with an
increase in BrdU incorporation (http://www.case.edu/
artsci/biol/skeletal/24114569s.html). CNP overexpres-
sion reduced the clinical arthritis score in the K/BxN
TCR mice, with a mean  SD arthritis score of 4.37 
1.38 in CNP-overexpressing mice (n  8) compared to
8.66  3.26 in the K/BxN TCR mice (n  14) (P  0.05
by t-test).
CNP overexpression also reduced the severity
of articular cartilage inflammation and damage in the
K/BxN TCR mice (Figure 3E). Thirteen-week-old male
mice with CNP overexpression had better articular
cartilage chondrocyte distribution and organization and
cartilage matrix content than the controls. Although
CNP overexpression appeared to protect articular carti-
lage against damage caused by inflammation (Figures
4A–C), overexpression did not reduce inflammation-
Figure 3. C-type natriuretic peptide (CNP) overexpression reduces growth retardation in K/BxN T cell receptor (TCR) mice. A, Breeding strategy
used to generate K/BxN TCR mice that overexpress CNP in chondrocytes. Grey coat color indicates the KRN TCR transgene (25). B, Development
of arthritis without growth retardation in K/BxN TCR,Col2a1-NPPC–transgenic mice. Nose-to–tail tip lengths of male and female K/BxN
TCR,Col2a1-NPPC–transgenic mice and K/BxN TCR mice are shown. Statistical analysis revealed a significant difference (P  0.05 by F test)
between K/BxN and K/BxN TCR,Col2a1-NPPC–transgenic mice at week 10 (n  16 and n  6, respectively), week 13 (n  7 and n  5, respectively),
week 15 (n  14 and n  6, respectively), week 20 (n  7 and n  5, respectively), and week 26 (n  7 and n  5, respectively). Values are the
mean  SD. C, Hematoxylin and eosin–stained coronal sections of proximal tibia growth plates of a 12-week-old nontransgenic mouse (BxN) (a),
an arthritic mouse (K/BxN) (b), an arthritic and CNP-overexpressing mouse (K/BxN TCR,Col2a1-NPPC–transgenic) (c), and a CNP-overexpressing
mouse (Col2a1-NPPC–transgenic) (d). Original magnification  20. D, Radiographs of lower extremities of 12-week-old male K/BxN mice with and
without the Col2a1-NPPC transgene and/or the TCR transgene. E, Histologic scores from evaluation of inflammation, scores based on International
Cartilage Repair Society (ICRS) system II evaluation, and scores based on ICRS system III evaluation in arthritic mice with (K/BxN
TCR,Col2a1-NPPC) and without (K/BxN) CNP overexpression. Values are the mean  SD.   P  0.05 versus mice with CNP overexpression.
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4D).
CNP overexpression enhances signal transduc-
tion via NPR-B and reduces the sensitivity of this
signaling pathway to the proinflammatory cytokines
TNF and IL-1. We performed cGMP enzyme-linked
immunosorbent assays, real time qPCR, and Western
blotting using cultures of rib cartilage primary chondro-
cytes harvested from Col2a1-NPPC–transgenic and WT
control mice. The mean  SD intracellular cGMP level
in the Col2a1-NPPC–transgenic mouse chondrocytes
was 8  0.7–fold higher than in the WT mouse
chondrocytes, confirming enhanced CNP signaling. In
Col2a1-NPPC–transgenic mouse chondrocytes, levels of
protein and mRNA for NPR-B (Npr2) were increased
(Figures 5, 6A, and online at http://www.case.
Figure 4. C-type natriuretic peptide (CNP) overexpression lessens cartilage damage in K/BxN T cell receptor (TCR) mice. A and B,
Photomicrographs of hematoxylin and eosin (H&E)–stained sagittal sections of the femorotibial joint of a 13-week-old male nontransgenic mouse
(BxN), an arthritic mouse (K/BxN), a CNP-overexpressing mouse (Col2a1-NPPC–transgenic), and an arthritic and CNP-overexpressing mouse
(K/BxN TCR,Col2a1-NPPC–transgenic). Femoral articular cartilage is shown (arrows). The images shown are from mice that had the median score
for histologic severity within each genotypic group. Original magnification  10 in A;  40 in B. C, Photomicrographs of Safranin O–stained coronal
sections of the femorotibial joints of 12-week-old female mice. The cartilage surface of the tibia plateau is shown (arrows). Bars  100 m. D,
Photomicrographs of H&E-stained sagittal sections of the femorotibial joint of 12-week-old female mice. Although K/BxN TCR,Col2a1-NPPC–
transgenic mice have pannus and synovial inflammation (solid arrows), there is less damage to the articular cartilage surface (dashed arrows). Bars 
100 m.
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transgenic mouse chondrocytes also had increased ex-
pression of mRNA for the pro-chondrogenic growth fac-
tors Vegf and Tgfb1 and increased expression of Col2a1
compared to WT mouse chondrocytes (Figure 5).
Immunostaining revealed that vascular endothe-
lial growth factor (VEGF) was expressed in a wider
region of the growth plate of Col2a1-NPPC–transgenic
mice (available online at http://www.case.edu/artsci/biol/
skeletal/24114569s.html). VEGF staining was found to
encompass an area that surrounds not only the hyper-
trophic and proliferating chondrocytes, but also the
trabecular bone beneath the hypertrophic chondrocytes
where the blood vessels reside (http://www.case.edu/
artsci/biol/skeletal/24114569s.html). In addition, as has
been previously reported (32), we confirmed that p38
MAPK phosphorylation is increased and MAPK ERK-1
phosphorylation is decreased in CNP-overexpressing
chondrocytes compared to WT mouse chondrocytes
(Figure 6B). We also observed that expression of mRNA
for matrix metalloproteinase 3 (MMP-3), MMP-9, and
MMP-13 was mildly increased in Col2a1-NPPC–
transgenic mouse chondrocytes as compared to WT
mouse chondrocytes (Figure 6C).
Since CNP overexpression in Col2a1-NPPC–
transgenic mice appeared to protect articular cartilage
in vivo against the damaging effect of inflammation, we
treated primary chondrocytes from Col2a1-NPPC–
transgenic mice and control mice with the proinflamma-
tory cytokines TNF and IL-1. TNF and IL-1 each
significantly reduced Npr2 mRNA expression in both
Col2a1-NPPC–transgenic and WT mouse chondrocytes.
However, Npr2 mRNA expression in Col2a1-NPPC–
transgenic mouse chondrocytes after TNF or IL-1
treatment was comparable to Npr2 expression in un-
treated WT mouse chondrocytes (Figure 6A).
In Col2a1-NPPC–transgenic mouse chondro-
cytes, TNF exposure had no effect on p38 MAPK
phosphorylation, whereas IL-1 reduced p38 MAPK
phosphorylation (Figure 6B). In contrast, both treat-
ment with TNF and treatment with IL-1 increased
p38 MAPK phosphorylation in WT mouse chondro-
cytes. The expression of mRNA for the MMPs was
either the same or less elevated in Col2a1-NPPC–
transgenic mouse chondrocytes compared to WT mouse
chondrocytes following exposure to these cytokines (P 
0.05) (Figure 6C).
It has been reported that IGF-1, IGF receptor I,
and IGFBP-3 levels are diminished in serum of chil-
dren with JIA, accounting for the delay in longitudinal
growth. To understand whether CNP overexpression
affects Igf1, Igf1r, and Igfbp3 mRNA expression, we
performed real-time qPCR using primary chondrocyte
cultures of rib cartilage harvested from Col2a1-NPPC–
transgenic and WT mice. Col2a1-NPPC–transgenic
mouse primary chondrocytes did not have increased
levels of mRNA for Igf1 or Igf1r, but did have 6–7-fold
increased levels of mRNA for Igfbp3 compared to WT
mouse chondrocytes. When exposed to TNF (10 ng/ml)
and IL-1 (10 ng/ml) overnight, Igf1 and Igf1r expression
levels in chondrocytes were suppressed significantly in
both Col2a1-NPPC–transgenic and WT mouse chondro-
cytes. Interestingly, Igfbp3 expression levels did not
differ between Col2a1-NPPC–transgenic and WT mouse
chondrocytes exposed to proinflammatory cytokines; in
addition, Igfbp3 expression remained up-regulated in the
Col2a1-NPPC–transgenic mouse chondrocytes (avail-
able online at http://www.case.edu/artsci/biol/skeletal/
24114569s.html).
Earlier reports indicate that TNF and IL-1
inhibit chondrocyte differentiation and DNA synthesis
in growth plate and costal chondrocytes by suppressing
Sox9 expression (33). It is known that CNP up-regulates
Sox9 expression in chondrocytes (34,35). Thus, we
sought to determine whether CNP overexpression in
primary chondrocytes from Col2a1-NPPC–transgenic
mice also up-regulates Sox9 mRNA expression. Results
showed that in primary chondrocytes from Col2a1-
NPPC–transgenic mice, Sox9 expression is up-regulated
Figure 5. C-type natriuretic peptide overexpression in chondrocytes
increases the expression of genes associated with cartilage anabolism.
Results of quantitative real-time polymerase chain reaction analysis of
primary chondrocyte cultures recovered from Col2a1-NPPC–
transgenic mice and wild-type (WT) mice for several genes associated
with cartilage growth are shown. Values are the mean  SD.   P 
0.05.
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expected, when chondrocytes were exposed to TNF
overnight, Sox9 expression was reduced in both WT and
Col2a1-NPPC–transgenic mouse chondrocytes, but in
Col2a1-NPPC–transgenic mouse chondrocytes that re-
duction brought Sox9 expression to the level seen in
untreated WT mice (Figure 6D). We suggest that CNP
overexpression in Col2a1-NPPC–transgenic mice pro-
tected against down-regulation of Sox9 expression levels
during TNF exposure.
DISCUSSION
It has been posited that in children with JIA the
inhibitory effects of proinflammatory cytokines (IL-6,
TNF, and IL-1 ) on growth plate chondrocytes con-
tribute to growth suppression (36,37). Elevation of pro-
inflammatory cytokines (e.g., TNF and IL-1) in syno-
vial fluid has also been associated with destruction of
growth plates adjacent to an arthritic joint. Proinflam-
matory cytokines decrease the width of the proliferating
zone in growth plate cartilage, which leads to a decrease
in endochondral bone growth. IL-1 has been shown to
reduce expression of cartilage collagens and proteogly-
cans (13,38).
In this study, we tested whether the growth-
promoting effects of the CNP/NPR-B signaling pathway
would lessen the severity of growth failure and cartilage
degeneration in a mouse model of inflammatory arthri-
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Figure 6. C-type natriuretic peptide (CNP) overexpression in chondrocytes dampens the response to inflammatory cytokines. A, Relative levels of
mRNA for Npr2 in primary cultures obtained from nontransgenic and Col2a1-NPPC–transgenic mice that had or had not been exposed to tumor
necrosis factor  (TNF) (10 ng/ml) and interleukin-1 (IL-1) (10 ng/ml). B, Western blot analysis of p44 ERK-1 and p38 MAPK phosphorylation.
ERK-1 phosphorylation was inhibited by the CNP transgene. TNF treatment increased p44 ERK-1 phosphorylation in mouse chondrocytes (even
in those from CNP-transgenic mice), but IL-1 treatment did not change suppression of p44 ERK-1 phosphorylation in Col2a1-NPPC–transgenic
mouse chondrocytes. Phosphorylation of p38 MAPK was increased in Col2a1-NPPC–transgenic mouse cartilage as compared to cartilage from
nontransgenic littermates. Overnight treatment with TNF or IL-1 significantly increased the p38 phosphorylation in nontransgenic mouse
chondrocytes, while this effect was only modest in the Col2a1-NPPC–transgenic mice. C, Real-time quantitative polymerase chain reaction (qPCR)
analysis of matrix metalloproteinase 3 (MMP-3), MMP-9, and MMP-13 in primary chondrocytes isolated from the rib cages of wild-type (WT) and
Col2a1-NPPC–transgenic mice. D, Real-time qPCR analysis of SOX9 transcription factor in primary chondrocytes isolated from the rib cages of WT
and Col2a1-NPPC–transgenic mice. Values in A, C, and D are the mean  SD, normalized to levels in WT mice.   P  0.05.
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in chondrocytes resulting in increased chondrocyte pro-
liferation, matrix production, and hypertrophic chondro-
cyte size, consistent with previous reports (2). We then
bred the transgene for CNP overexpression into the
K/BxN TCR mouse model of chronic inflammatory
arthritis and observed that CNP overexpression reduced
the damaging effects of chronic inflammatory arthritis
on linear growth and articular cartilage.
There are several possible mechanisms by which
CNP overexpression protects growth plate and articular
cartilage against inflammation-induced damage. One
possibility is that CNP overexpression increases chon-
drocyte functioning, thereby blunting the consequences
of the negative effects of inflammatory cytokines. Inter-
estingly, activation of MAPKs, particularly p38 MAPK,
is a critical event that leads to the production of several
mediators of cartilage damage, including the MMPs, in
an arthritic joint (39). Therefore, it was surprising that
overexpression of CNP protected articular cartilage
while also significantly increasing p38 MAPK phosphor-
ylation. CNP signaling may favor the activation of ana-
bolic pathways downstream of p38 MAPK, whereas
inflammatory cytokines favor the activation of catabolic
pathways.
It has been suggested that growth delay in chil-
dren with JIA is due, at least in part, to reduced levels of
IGF-1 and IGFBP-3. Therefore, we studied the effect of
CNP overexpression on Igf1 mRNA expression in the
primary chondrocytes isolated from rib cage cartilage of
Col2a1-NPPC–transgenic mice and WT mice, using real-
time qPCR. Results showed that while there was no
significant suppressive effect of CNP overexpression on
Igf1 and Igf1r, there was a significant increase in Igfbp3
expression levels. In a previous human study, the inves-
tigators showed that a patient with acromesomelic dys-
plasia, Maroteaux type lacking NPR2 function had low
serum levels of IGF-1. It may be possible that lack of
CNP signaling negatively regulates IGF-1 levels. How-
ever, patients with acromesomelic dysplasia, Maroteaux
type have skeletal dysplasia that is distinct from that
seen in IGF-1 deficiency. Furthermore, patients with
this disease are able to produce IGF-1 when an IGF-1
generation test is performed (40). Our data on the
Col2a1-NPPC–transgenic mice do not suggest any direct
regulatory effects of excess CNP on IGF-1 signaling
pathway.
Igf1 expression and Igf1r expression were simi-
larly suppressed in both Col2a1-NPPC–transgenic
mouse primary chondrocytes and WT mouse chondro-
cytes when cultures were exposed to TNF and IL-1
overnight, while Igfbp3 expression remained up-
regulated. However, in the absence of a significant
change in Igf1 and Igf1r expression in Col2a1-NPPC–
transgenic mouse chondrocytes, we do not believe the
protective effects of CNP seen in cartilage are due to its
regulatory effects on Igf1 signaling.
Earlier reports have indicated that TNF and
IL-1 inhibit chondrocyte differentiation by suppressing
DNA synthesis in the growth plate and costal chondro-
cytes (33). TNF suppresses DNA synthesis, chondro-
cyte differentiation, and matrix synthesis by unknown
mechanisms (41). It has been suggested that TNF
suppresses expression of Sox9, a key chondrocyte tran-
scription factor, in inflamed cartilage. Our data suggest
that CNP might improve chondrocyte proliferation and
differentiation during inflammation by its regulatory
effect on Sox9 expression. Sox9 mRNA expression was
up-regulated 5-fold in chondrocytes of Col2a1-NPPC–
transgenic mice. SOX9 and CNP are both known to
increase matrix synthesis (42). Although Sox9 expression
was significantly reduced following TNF exposure in
Col2a1-NPPC–transgenic mouse chondrocytes, expres-
sion was comparable to the level found in untreated WT
mouse chondrocytes. Thus, it can be speculated that
CNP expression overcomes the effect of proinflamma-
tory cytokines on cartilage at the level of transcription
factor Sox9 expression. Sox9 regulates chondrocyte dif-
ferentiation, which is needed not only for longitudinal
growth, but also for the matrix production that maintains
the cartilage integrity.
We also cannot rule out the possibility that CNP
overexpression directly modulates the inflammatory re-
sponse. It has been reported that CNP inhibits cytokine-
induced leukocyte rolling and has an antiplatelet/
antithrombotic effect (43). Reports suggest that CNP
secretion by vascular endothelial cells is increased in
response to inflammatory stimuli such as IL-1, TNF,
and lipopolysaccharide (44,45). Additionally, CNP sup-
presses lipopolysaccharide-activated murine macro-
phage secretion of prostaglandin E2 (46) and inhibits
vascular inflammation and intimal hyperplasia in exper-
imental vein grafts (47). Therefore, it is possible that
CNP overexpression protects growth and prevents joint
damage by diminishing chronic inflammation. Conse-
quently, studies investigating the antiinflammatory ef-
fects of CNP in models of arthritis are warranted. While
our data demonstrate that linear growth retardation in
K/BxN TCR mice can be prevented by CNP overexpres-
sion, it remains to be determined whether this protective
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mation and whether pharmacologic manipulation of the
CNP signaling pathway will have similar effects.
Reduction in linear growth is one complication of
joint inflammation. Another common complication is
widening of the metaphysis, which has been attributed to
neovascularization and VEGF overexpression in the
growth plate. CNP may play a role in this neovascular-
ization, since chondrocytes that overexpress CNP were
shown to produce increased Vegf mRNA levels (Figure
5), and VEGF immunostaining revealed an area that
encompasses hypertrophic and proliferating chondro-
cytes, as well as the trabecular bone where the blood
vessels reside (available online at http://www.case.edu/
artsci/biol/skeletal/24114569s.html). Consequently,
Col2a1-NPPC–transgenic mice developed widening at
the ends of their long bones. We did not observe
worsening periarticular overgrowth in the K/BxN TCR,
Col2a1-NPPC–transgenic mice, perhaps because of the
protective effect of CNP overexpression on the chondro-
cyte response to inflammatory cytokines. However, fur-
ther studies are needed. An analog of CNP has been
shown to improve skeletal growth in mice harboring a
knockin Fgfr3 allele that causes thanatophoric dysplasia
in humans (48). It will be interesting to determine
whether this analog will be able to improve the cartilage
phenotype in K/BxN TCR mice.
CNP overexpression by mouse chondrocytes pre-
vented endochondral growth delay and reduced articular
cartilage damage in a mouse model of systemic inflam-
matory arthritis. The likely mechanism for this effect is
a cell-autonomous increase in chondrocyte differentia-
tion, proliferation, hypertrophy, and matrix production,
and a cell-autonomous resistance to the growth-
suppressive effects of proinflammatory cytokines. These
data suggest that the CNP/NPR-B pathway may repre-
sent a novel therapeutic target to preserve growth plate
and joint cartilage integrity during systemic inflamma-
tory diseases. Although our findings are of particular
relevance to JIA, their impact may extend to other forms
of inflammatory arthritis and other inflammatory dis-
eases of childhood that stunt longitudinal growth, such
as inflammatory bowel disease.
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